MK 8245Alternative Names: MK-8245
Latest Information Update: 17 Jun 2011
At a glance
- Originator Merck & Co
- Class Antihyperglycaemics
- Mechanism of Action Stearoyl CoA desaturase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Suspended Type 2 diabetes mellitus
Most Recent Events
- 13 Nov 2008 Merck initiates enrolment in a phase I trial for Type-2 diabetes mellitus in USA